Searchable abstracts of presentations at key conferences in endocrinology

ea0081ep1047 | Thyroid | ECE2022

Thyroid incidental uptake at 18F-FDG PET/CT, an alert to malignancy - a case report

Manique Ines , Cortez Lui sa , Silva-Nunes Jose

Introduction: Thyroid incidentaloma in 18F-FDG PET-CT is relatively common and the most focal uptake are benign. However, the risk of malignancy of thyroid lesions with focal uptake on 18F-FDG PET-CT is 34.8%. Metastasis to the thyroid is uncommon (less than 0.2% of thyroid fine needle aspiration – FNA - puncture findings), with renal neoplasms being the most frequently associated (48.1%) and, more rarely, those from the breast (7.8%).Case report: A...

ea0090p706 | Pituitary and Neuroendocrinology | ECE2023

Rare causes of adrenal tumours and the possible role of adrenal arterial embolization - two case reports

Manique Ines , Cortez Luisa , Abreu Silvestre , Silva-Nunes Jose

Introduction: Adrenal oncocytoma (AO) and ganglioneuroma (GN) are rare causes of adrenal masses, corresponding usually to nonfunctional and benign tumors. However, 20% of the AO shows some elements of malignancy and 10–20% of them affect adrenal hormone production. GNs account for 0.3%-2% of adrenal incidentalomas, with punctate calcifications in CT imaging being highly suggestive. However, preoperative differential diagnosis remains challenging. Adrenal arterial emboliza...

ea0081p760 | Thyroid | ECE2022

Added value for Graves’ orbitopathy management in a tertiary center – report of four cases

Manique Ines , Amaral Sara , Cortez Luisa , Palha Ana , Duarte Ana , Silva-Nunes Jose

Introduction: Graves orbitopathy is the major extrathyroidal manifestation of Graves Disease (GD). The approach depends on its clinical activity and severity. Treatment and referral to specialized centers, with Endocrinology and Ophthalmology, has a strong impact on the prognosis of Graves’ Disease (GD) and GO.Cases report: We report four cases of DG with OG. Their characteristics and clinical evolution are shown in Table 1.<table boarder="1" ce...

ea0090rc1.5 | Rapid Communications 1: Diabetes, Obesity, Metabolism and Nutrition 1 | ECE2023

Continuous subcutaneous insulin infusion (CSII) and growth in children with type 1 diabetes

Araujo Catia , Manique Ines , Baptista Carla , Paiva Isabel , Mirante Alice , Caetano Joana , Cardoso Rita , Dinis Isabel

Introduction: Type 1 diabetes (T1D) is the most frequent children’s endocrinopathy in Portugal. The duration of the disease and metabolic control may affect the final height of pediatric patients. Despite the metabolic advantages of technological advances, such as continuous subcutaneous insulin perfusion (CSII), the effect on growth is unclear.Aim: To assess the impact of T1D treatment, with multiple daily injections (MDI) or CSII, on growth.<p...

ea0090ep703 | Pituitary and Neuroendocrinology | ECE2023

Silent pituitary macroadenomas – clinical behavior and prognosis

Manique Ines , Amaral Sara , Palha Ana , Cortez Luisa , Cerqueira Luis , Sagarribay Amets , Silva-Nunes Jose

Introduction: A third of pituitary adenomas are non-functioning. Classification depends on adenohypophyseal hormones expression and transcription factors.Aim: Characterize silent pituitary macroadenomas cases regarding their clinical data, treatment, histopathology and prognosis.Methods: We revised clinical process of patients followed in CHULC. Cases with non-access to clinical follow-up registries or exams were excluded.<p cl...

ea0090p135 | Pituitary and Neuroendocrinology | ECE2023

Prolactinomas under high doses cabergoline in portuguese patients: The Resistant Prolactinoma Study

Manique Ines , Benido Silva Vania , Carvalho Davide , Marques Olinda , Nobre Ema , Joao Bugalho Maria , Palha Ana , Ribeiro Isabel , Pereira Josue , Almeida Rui , Sagarribay Amets , Cerqueira Luis , Amaral Claudia

Background: In 15% of prolactinomas there is dopamine agonist(DA) resistance. The clinical characteristics, the best diagnostic and therapeutic management of these cases have not been established so far.Aim: To characterize patients taking a high dose cabergoline(≥ 3mg/week) and then describe clinical, biochemical and imaging features of cabergoline-resistant cases.Methods: Retrospective study with 5 centers representing the ...